ERBB2 and breast cancer: Currently there is no curative treatment for metastatic HER2-positive breast cancer; therefore, biomarkers which can identify at diagnosis patients unlikely to benefit from TCH based treatment are critical to allow clinicians to direct these patients to alternate therapeutic options.